<DOC>
	<DOCNO>NCT00362544</DOCNO>
	<brief_summary>This pilot study design order evaluate safety efficacy AmBisome loading dose regimen , weekly administration schedule , aplastic phase follow induction consolidation chemotherapy acute leukaemia , initial phase allogeneic stem-cell transplant , high risk period far severe fungal infection development concern .</brief_summary>
	<brief_title>PROPHYSOME : Pilot Study Safety Weekly Administration 10mg/kg AmBisome® Antifungal Prophylaxis Treatment Allogeneic Stem-cell Transplantation Acute Leukaemia</brief_title>
	<detailed_description>This pilot study design order evaluate safety efficacy AmBisome loading dose regimen , weekly administration schedule , aplastic phase follow induction consolidation chemotherapy acute leukaemia , initial phase allogeneic stem-cell transplant , high risk period far severe fungal infection development concern .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>Male female patient age 18 , Patients undergo standard myeloablative , condition regimen AGVHD ciclosporin prophylaxis allogeneic stem cell transplantation , Patients acute leukaemia undergo first induction therapy second induction therapy relapse , consolidation therapy , Expected neutropenia &lt; 0.5 giga/l least 2 week , Normal chest CT scan and/or normal Xray chest baseline , Patients sign symptom fungal infection previous proven probable IFI , Females childbearing potential must surgically incapable pregnancy , practise acceptable method birth control negative pregnancy test ( blood urine ) baseline , Understanding study agreement patient give write informed consent , Ability agreement comply study requirement , Patient willing attend hospital appointment injection ( infusion perform hospital , strict medical supervision ) . All patient hospitalise prior , remain hospital least one day , first infusion . Known hypersensitivity amphotericin B , particular know history anaphylactic reaction amphotericin B , Patients undergo cord transplantation , Creatinine clearance &lt; 60 ml/min , Patient moderate severe liver disease define AST ALT &gt; 5 time upper limit normal ( ULN ) , Patients unlikely survive 1 month , Febrile patient ( ≥ 38.5°C ) , Patients receive systemic antifungal therapy within 15 day prior inclusion , Any severe cardiovascular disease ( arrhythmias , particular ) may constitute contraindication AmBisome® administration , Any severe disease haematological disease describe second inclusion criterion , investigator 's judgement may interfere study evaluation affect patient 's safety , Pregnant nursing female , Patients previously include study , Patients take investigational drug last 30 day prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>antifungal prophylaxis</keyword>
	<keyword>allogeneic stem-cell transplantation</keyword>
	<keyword>acute leukaemia</keyword>
	<keyword>antifungal prophylaxis treatment allogeneic stem-cell transplantation acute leukaemia</keyword>
</DOC>